相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma
Elif Karaca Atabay et al.
BLOOD (2022)
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
Hugo Larose et al.
HAEMATOLOGICA (2021)
Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)
Yeseul Kim et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma
Tingting Liu et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2021)
The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report
Zhaoting Meng et al.
CANCER BIOLOGY & THERAPY (2021)
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next- generation sequencing
Yen-Ting Lin et al.
EUROPEAN JOURNAL OF CANCER (2021)
NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
Elissa Andraos et al.
CANCERS (2021)
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1
Eric J. Lowe et al.
BLOOD (2021)
Targeted based therapy in nodal T-cell lymphomas
Dai Chihara et al.
LEUKEMIA (2021)
Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy A case report
Kyoko Yamaguchi et al.
MEDICINE (2021)
Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling
Ping Yang et al.
ONCOTARGETS AND THERAPY (2021)
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
Petra Ross-Macdonald et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
Wout De Wispelaere et al.
CANCERS (2021)
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Lingyue Gao et al.
DRUG RESISTANCE UPDATES (2021)
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
Estela Sanchez-Herrero et al.
MOLECULAR ONCOLOGY (2021)
Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer
Moushumi Suryavanshi et al.
CANCER GENETICS (2021)
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Rudolf M. Huber et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms
Noriko Yanagitani et al.
CANCER SCIENCE (2020)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2020)
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Robert Chen et al.
CLINICAL CANCER RESEARCH (2020)
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
Soumya S. Rajan et al.
ONCOGENE (2020)
Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1
Hengyi Chen et al.
CELL DEATH & DISEASE (2020)
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Laura Strauss et al.
SCIENCE IMMUNOLOGY (2020)
Overcoming resistance by ALK compound mutation (I1171S+G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
Ken Takahashi et al.
THORACIC CANCER (2020)
Identification of ALK in Thinness
Michael Orthofer et al.
CELL (2020)
A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models
Wei Wei et al.
CLINICAL CANCER RESEARCH (2020)
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
Edyta M. Urbanska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
Ruoshi Shi et al.
LUNG CANCER (2020)
Precision Medicine Management of Chronic Lymphocytic Leukemia
Riccardo Moia et al.
CANCERS (2020)
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
Miriam Grazia Ferrara et al.
CANCERS (2020)
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
Nina Prokoph et al.
BLOOD (2020)
CD30 and ALK combination therapy has high therapeutic potency inRANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma
Ashleigh M. Fordham et al.
BRITISH JOURNAL OF CANCER (2020)
Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
Abhay Singh et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report
Roberta Minari et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212)
Emily Greengard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial
Reiji Fukano et al.
CANCER SCIENCE (2020)
Targeting p53 in chronic lymphocytic leukemia
Riccardo Moia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics
Jianzhong Chen et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2020)
Coexisting of COX7A2L-ALK, LINC01210-ALK, ATP13A4-ALK and Acquired SLCO2A1-ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report
Chengzhi Cai et al.
ONCOTARGETS AND THERAPY (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
Lara Mussolin et al.
CANCERS (2020)
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
Valerio Gristina et al.
PHARMACEUTICALS (2020)
ALK-transformed mature T lymphocytes restore early thymus progenitor features
Annabelle Congras et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Finding the hot spot: identifying immune sensitive gastrointestinal tumors
Andre Luiz Pitanga Bastos De Souza
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity
Bo Wang et al.
THERANOSTICS (2020)
Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
Kartik Sehgal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
Dai Chihara et al.
HEMATOLOGICAL ONCOLOGY (2019)
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
Takahiro Tsuji et al.
MOLECULAR CANCER RESEARCH (2019)
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
Philippe Jamme et al.
CLINICAL LUNG CANCER (2019)
Current management of neuroblastoma and future direction
Elizabeth R. Pastor et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
Stephen P. Ducray et al.
CANCERS (2019)
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib
Niamh Coleman et al.
LUNG CANCER (2019)
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells
David N. Debruyne et al.
NATURE (2019)
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Daniele Cretella et al.
CANCERS (2019)
Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy
Esther R. Berko et al.
CANCER CELL (2019)
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
Geeta G. Sharma et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Response to Combination of Metformin and Nivolumab in a NSCLC Patient Whose Disease Previously Progressed on Nivolumab
P. Viveiros et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
Ricky M. Trigg et al.
NATURE COMMUNICATIONS (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Koutaroh Okada et al.
EBIOMEDICINE (2019)
Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Fabian Knoerr et al.
HAEMATOLOGICA (2018)
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions
Young Kwang Chae et al.
ONCOLOGIST (2018)
Efficacy of nivolumab in a patientwith systemic refractory ALK plus anaplastic large cell lymphoma
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2018)
Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Fabian Knoerr et al.
HAEMATOLOGICA (2018)
Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC
Jing Guo et al.
CANCER BIOLOGY & THERAPY (2018)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
The AP-1-BATF and-BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma
Nikolai Schleussner et al.
LEUKEMIA (2018)
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
Xinghao Ai et al.
LUNG CANCER (2018)
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Brandon Golding et al.
MOLECULAR CANCER (2018)
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
Pang-Dian Fan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Satoshi Yoda et al.
CANCER DISCOVERY (2018)
Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
Amila K. Nanayakkara et al.
SCIENTIFIC REPORTS (2018)
Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1
Songchao Li et al.
CELL AND BIOSCIENCE (2018)
ALK in Neuroblastoma: Biological and Therapeutic Implications
Ricky M. Trigg et al.
CANCERS (2018)
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Nina Prokoph et al.
CANCERS (2018)
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Geeta Geeta Sharma et al.
CANCERS (2018)
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Kim Tam Bui et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer
Sara Redaelli et al.
CANCER RESEARCH (2018)
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Franco Locatelli et al.
LANCET HAEMATOLOGY (2018)
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Viola W. Zhu et al.
LUNG CANCER-TARGETS AND THERAPY (2018)
The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas
Makoto Miyazaki et al.
CELL DEATH DISCOVERY (2018)
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target
Michael T. Werner et al.
BLOOD (2017)
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium
Frank M. Balis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
Masayoshi Miyawaki et al.
MOLECULAR CANCER RESEARCH (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib
Viola W. Zhu et al.
LUNG CANCER (2017)
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Barbara Pro et al.
BLOOD (2017)
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
M. Ceccon et al.
ONCOGENE (2016)
ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
D. N. Debruyne et al.
ONCOGENE (2016)
Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
Holger Hebart et al.
ANNALS OF INTERNAL MEDICINE (2016)
Anaplastic large cell lymphoma in paediatric and young adult patients
Suzanne D. Turner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
Yoon Jin Cha et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
Shiro Fujita et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature
Maria Cecilia Mengoli et al.
LUNG CANCER (2016)
Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors
Delphine Levacq et al.
LUNG CANCER (2016)
A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib
Sandeep Kodityal et al.
LUNG CANCER (2016)
Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress
Tim I. M. Malcolm et al.
NATURE COMMUNICATIONS (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli et al.
ONCOTARGET (2016)
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK plus tumors
Amit Dipak Amin et al.
ONCOTARGET (2016)
Challenging perspectives on the cellular origins of lymphoma
Tim I. M. Malcolm et al.
OPEN BIOLOGY (2016)
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells
Xuyuan Dong et al.
NEOPLASIA (2016)
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Amit Dipak Amin et al.
CANCER RESEARCH (2015)
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
Rishil J. Kathawala et al.
DRUG RESISTANCE UPDATES (2015)
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib
Gouji Toyokawa et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert Chen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
Luca Mologni et al.
ONCOTARGET (2015)
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
Geraldine Mitou et al.
ONCOTARGET (2015)
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
Diletta Fontana et al.
CANCER MEDICINE (2015)
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Akihiro Kogita et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
M. Ceccon et al.
MOLECULAR CANCER RESEARCH (2015)
Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin
N. Moti et al.
ONCOGENE (2015)
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
Cheng Ji et al.
CANCER BIOLOGY & THERAPY (2014)
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Tatsushi Kodama et al.
CANCER LETTERS (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
Akihiro Kogita et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
Daria Zdzalik et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
Advanced Stage Anaplastic Large Cell Lymphoma in Children and Adolescents: Results of ANHL0131, a Randomized Phase III Trial of APO Versus a Modified Regimen With Vinblastine: A Report From the Children's Oncology Group
Sarah Alexander et al.
PEDIATRIC BLOOD & CANCER (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
Azusa Tanimoto et al.
ONCOTARGET (2014)
The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD4+ T Lymphocytes
Qian Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Malignant Transformation of CD4+ T Lymphocytes Mediated by Oncogenic Kinase NPM/ALK Recapitulates IL-2-Induced Cell Signaling and Gene Expression Reprogramming
Michal Marzec et al.
JOURNAL OF IMMUNOLOGY (2013)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon et al.
MOLECULAR CANCER RESEARCH (2013)
Central nervous system involvement in anaplastic large cell lymphoma in childhood: Results from a multicentre European and Japanese study
Denise Williams et al.
PEDIATRIC BLOOD & CANCER (2013)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns
C. Laurent et al.
LEUKEMIA (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2011)
Safety Assessment of Intensive Induction Therapy in Childhood Anaplastic Large Cell Lymphoma: Report of the ALCL99 Randomised Trial
Grazyna Wrobel et al.
PEDIATRIC BLOOD & CANCER (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Takaaki Sasaki et al.
CANCER RESEARCH (2010)
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial
Marie-Cecile Le Deley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner
Yu-Xin Cui et al.
BLOOD (2009)
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
Ping Shi et al.
BLOOD (2009)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53
E. Drakos et al.
LEUKEMIA (2009)
Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications
James G. Bilsland et al.
NEUROPSYCHOPHARMACOLOGY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms
Suzanne D. Turner et al.
CELLULAR SIGNALLING (2007)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
Monika Kasprzycka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine
TB Obey et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma
GZ Rassidakis et al.
LEUKEMIA (2005)
Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma
L Mussolin et al.
LEUKEMIA (2005)
Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling
I Bonzheim et al.
BLOOD (2004)
Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase
SD Turner et al.
ONCOGENE (2003)
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas, and plasma cell tumors
R Chiarle et al.
BLOOD (2003)
Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways:: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors
CM Cabrera et al.
TISSUE ANTIGENS (2003)
Cytogenetic characterization of chromosomal rearrangement in a human vinblastine-resistant CEM cell line: use of comparative genomic hybridization and fluorescence in situ hybridization
S Struski et al.
CANCER GENETICS AND CYTOGENETICS (2002)
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma
Q Zhang et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
